Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

被引：0

作者：

Inzucchi, S. E. ^{[1
]}

Khunti, K. ^{[2
]}

Fitchett, D. H. ^{[3
]}

Wanner, C. ^{[4
]}

Mattheus, M. ^{[5
]}

George, J. T. ^{[6
]}

Ofstad, A. P. ^{[7
]}

Zinman, B. ^{[8
]}

机构：

[1] Yale Sch Med, Sect Endocrinol, New Haven, CT USA

[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Wurzburg Univ Clin, Div Nephrol, Wurzburg, Germany

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Boehringer Ingelheim Norway KS, Asker, Norway

[8] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷

关键词：

Sodium glucose co-transport inhibitor 2; Cardioprotection; Heart failure;

D O I：

10.1016/j.metabol.2019.12.071

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：1

共 50 条

[31] CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
Inzucchi, Silvio E.
Zinman, Bernard
McGinniss, Jennifer
Schnee, Janet
George, Jyothis
Fitchett, David
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1656 - 1656
[32] Effects of Empagliflozin on Cardiac and Vascular Hemodynamic Markers by Subgroups of Age, Sex, and Hypertension in Patients with T2DM and High CV Risk: EMPA-REG OUTCOME
Chilton, Robert J.
Gullestad, Lars
Fitchett, David
Inzucchi, Silvio E.
Mattheus, Michaela
Woerle, Hans Juergen
Johansen, Odd Erik
DIABETES, 2017, 66 : A119 - A119
[33] Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial
Fitchett, David H.
Inzucchi, Silvio E.
Zinman, Bernard
Wanner, Christoph
Anker, Stefan D.
Pocock, Stuart
Kaspers, Stefan
George, Jyothis T.
Johansen, Odd Erik
Jamal, Waheed
Hantel, Stefan
Lund, Soren S.
CIRCULATION, 2020, 142
[34] Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome
Chilton, R. J.
Gullestad, L.
Fitchett, D.
Inzucchi, S. E.
Mattheus, M.
Woerle, H. J.
Johansen, O. E.
EUROPEAN HEART JOURNAL, 2017, 38 : 1251 - 1251
[35] Empagliflozin Reduces The Total Burden Of Cardiovascular Events Including Recurrent Events In The EMPA-REG OUTCOME Trial
Fitchett, D. H.
Inzucchi, S. E.
Wanner, C.
Anker, S. D.
Pocock, S.
Kaspers, S.
Johansen, O.
George, J. T.
Jamal, W.
Hantel, S.
Lund, S. S.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S88 - S88
[36] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular (CV) death with empagliflozin? Results from EMPA-REG OUTCOME
Inzucchi, S. E.
Fitchett, D.
Wanner, C.
Mattheus, M.
George, J. T.
Woerle, H. J.
Zinman, B.
DIABETOLOGIA, 2017, 60 : S425 - S425
[37] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
Fitchett, David
Butler, Javed
van de Borne, Philippe
Zinman, Bernard
Lachin, John M.
Wanner, Christoph
Woerle, Hans J.
Hantel, Stefan
George, Jyothis T.
Johansen, Odd Erik
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
EUROPEAN HEART JOURNAL, 2018, 39 (05) : 363 - 370
[38] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Fitchett, David
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Hantel, Stefan
Salsali, Afshin
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
[39] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman
Silvio E Inzucchi
John M Lachin
Christoph Wanner
Roberto Ferrari
David Fitchett
Erich Bluhmki
Stefan Hantel
Joan Kempthorne-Rawson
Jennifer Newman
Odd Erik Johansen
Hans-Juergen Woerle
Uli C Broedl
Cardiovascular Diabetology, 13
[40] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Zinman, Bernard
Inzucchi, Silvio E.
Lachin, John M.
Wanner, Christoph
Ferrari, Roberto
Fitchett, David
Bluhmki, Erich
Hantel, Stefan
Kempthorne-Rawson, Joan
Newman, Jennifer
Johansen, Odd Erik
Woerle, Hans-Juergen
Broedl, Uli C.
CARDIOVASCULAR DIABETOLOGY, 2014, 13

← 1 2 3 4 5 →